---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ARCHER"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ARCHER. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 85 evidence topics quoted from 31 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence/archer"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ARCHER

<a id="heading-3.1.2"></a>

## 3.1.2 ARCHER

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Registered objective: effect of intravitreal ANX007 on GA lesion growth rate

> “This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate.”
> “The results will be used to guide further development of ANX007 in participants with geographic atrophy.”
> “A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) - The ARCHER Study”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.1-2"></a>

#### Objective stated at trial initiation

> “The randomized, multi-center, double-masked Phase 2 trial is designed to evaluate the efficacy and safety of ANX007 in reducing the area of GA as evaluated by fundus autofluorescence (FAF) in patients with GA.”

Source: [Annexon Biosciences ARCHER initiation press release (2021)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-advances-classical-complement-platform-initiation-global)

<a id="topic-3.1.2.1-3"></a>

#### Objective stated with the topline results

> “ARCHER is a randomized, multi-center, double-masked, sham-controlled Phase 2 clinical trial comparing the safety and efficacy of ANX007 in patients with GA secondary to AMD.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Registered study dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2021-02-26” |
| Primary completion (actual) | “2023-03-28” |
| Study completion (actual) | “2023-09-13” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.2-2"></a>

#### Study site countries

| Country | Example site location in the registry record |
| --- | --- |
| United States | “Boston, Massachusetts, United States” |
| Australia | “Adelaide, South Australia, Australia” |
| New Zealand | “Wellington, New Zealand” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.2-3"></a>

#### Share of participants enrolled in the United States

> “Ninety-six percent of patients enrolled were from the United States.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.2-4"></a>

#### First participant dosed: March 2021

> “March 1, 2021”
> “announced that patient dosing has begun in its Phase 2 ARCHER study of its anti-C1q therapy, ANX007, to treat Geographic Atrophy (GA)”

Source: [Annexon Biosciences ARCHER initiation press release (2021)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-advances-classical-complement-platform-initiation-global)

<a id="topic-3.1.2.2-5"></a>

#### Enrollment completed: April 2022

> “April 07, 2022”
> “today announced the completion of enrollment in the Phase 2 ARCHER trial evaluating its anti-C1q candidate, ANX007, in patients with geographic atrophy (GA)”

Source: [Annexon Biosciences ARCHER enrollment press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-completes-enrollment-archer-phase-2-trial)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Registered design elements

| Design element | Registry record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.3-2"></a>

#### Randomized, double-masked, sham-controlled design with stratification

> “ARCHER is a randomized, multi-center, double-masked, sham-controlled Phase 2 clinical trial comparing the safety and efficacy of ANX007 in patients with GA secondary to AMD.”
> “The study enrolled a total of 270 patients, stratified by GA lesion size, location and choroidal neovascularization (CNV) in the fellow eye at the time of enrollment.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.3-3"></a>

#### Foveal and non-foveal lesions included

> “Randomized, double-masked”
> “Included foveal and non-foveal lesions”
> “Stratified for lesion location and lesion size”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.3-4"></a>

#### Twelve-month treatment period followed by six months off treatment

> “12 months (n=270)”
> “END OF STUDY Month 18 Off-treatment (6 months)”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

> “The total duration of participation is expected to be approximately 19 months.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.3-5"></a>

#### Visit schedule

> “visits were monthly through Month 12 and then at Months 15 & 18”

Source: [Chakravarthy (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Chakravarthy-Euretina.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Key inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Age | “50 Years and older” |
| Diagnosis | “Diagnosis of geographic atrophy of the macula secondary to age-related macular degeneration as determined by the Investigator and confirmed by the Central Reading Center.” |
| Lesion size | “Well-demarcated GA with a total area (baseline lesion size) ≥2.5 millimeter squared (mm^2)” |
| Multifocal lesions | “If GA is multifocal, at least 1 focal lesion must measure ≥1.25 mm^2 with the overall aggregate area of GA as specified above.” |
| Junctional zone autofluorescence | “Presence of hyper autofluorescence, any pattern, in the junctional zone of the GA. Absence of hyper autofluorescence (that is, pattern = none) is exclusionary.” |
| Lesion imaging | “The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any peripapillary atrophy.” |
| Visual acuity | “Normal luminance BCVA of 24 to 83 letters, inclusive, using ETDRS charts (20/25 to 20/320 Snellen equivalent, inclusive).” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.4-2"></a>

#### Key exclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Other causes of atrophy | “Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.” |
| Choroidal neovascularization | “Any evidence of choroidal neovascularization (CNV) in the study eye” |
| Myopia | “Spherical equivalent of -8.00 diopters (D) myopia or higher in the study eye.” |
| Glaucoma | “Uncontrolled glaucoma in the study eye (Intraocular pressure [IOP] >25 mmHg despite treatment with anti- glaucoma medication) or history of neovascular glaucoma.” |
| Prior ocular surgery | “History of glaucoma filtration surgery, minimally-invasive glaucoma surgery involving an implant, or vitrectomy surgery, or other procedure in the study eye that could affect drug distribution and/or clearance.” |
| Prior intravitreal treatment | “History of any prior IVT treatment for any indication in the study eye.” |
| Prior AMD treatment | “Any prior treatment for AMD in the study eye (for example, surgical, radiation, thermotherapeutic, or laser intervention), except oral supplements or minerals.” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.4-3"></a>

#### Enrollment of participants at high risk of progression

> “A randomized, controlled Phase 2 trial in GA patients who are at a high risk of progression is ongoing, and we anticipate reporting data from this trial in 2023.”

Source: [Annexon Biosciences Form 10-K (2021)](https://www.sec.gov/Archives/edgar/data/1528115/000156459021015262/annx-10k_20201231.htm)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Registered arms and interventions

| Arm | Quoted registry description |
| --- | --- |
| ANX007 Group 1, experimental | “ANX007 administered every month” |
| ANX007 Group 2, experimental | “ANX007 administered every other month” |
| Sham Group 3, sham comparator | “Sham injection administered every month” |
| Sham Group 4, sham comparator | “Sham injection administered every other month” |
| ANX007 formulation and route | “Form: solution for injection; Route of Administration: IVT” |
| Sham procedure | “Form and Route of Administration: pressure to mimic IVT injection” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.5-2"></a>

#### Dose, schedule, and randomized arms

> “Patients were randomized to receive an intravitreal dose of 5mg ANX007 monthly (n=89), 5mg ANX007 every other month (n=92) or sham monthly or every other month (pooled n=89) for a treatment period of 12 months, followed by a six-month off-treatment period.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.5-3"></a>

#### Injection volume in phase 2

> “Dosing: 5 mg / 100 microliters in Ph2”

Source: [EURETINA Congress (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-symposium.pdf)

<a id="topic-3.1.2.5-4"></a>

#### Dosing schedules planned at trial initiation

> “Monthly and every other month dosing schedules will be evaluated.”

Source: [Annexon Biosciences ARCHER initiation press release (2021)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-advances-classical-complement-platform-initiation-global)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Rate of Change in Geographic Atrophy Lesion Area by Fundus Autofluorescence as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint definition: GA lesion area slope by FAF through Month 12

> “Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area”
> “GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

> “The primary outcome measure of the study was the rate of change in GA lesion growth (slope) from baseline as measured by fundus autofluorescence through 12 months for the study eye.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-3.1.2.6.1-2"></a>

##### Sponsor rationale at trial start: natural history data and enrichment for fast progressors

> “Prior natural history data similar to that found in other recent large Phase 3 trials may provide a wealth of natural history data from nearly 2,000 patients on how to successfully enrich fast progressors of GA to enable an efficacy read-out within a one-year time period.”
> “The Phase 2 trial is designed to evaluate clinical effect on slowing of GA lesion growth, leveraging the natural history data and patient selection criteria of prior GA trials.”

Source: [Annexon Biosciences Form 10-K (2021)](https://www.sec.gov/Archives/edgar/data/1528115/000156459021015262/annx-10k_20201231.htm)

<a id="topic-3.1.2.6.1-3"></a>

##### Non-foveal lesions as a risk factor for faster lesion growth

> “Patients will be stratified by lesion location, with nearly half of enrolled participants having non-foveal lesions, a risk factor for more rapid progression.”
> “With nearly half of patients enrolled having non-foveal lesions, the ARCHER trial is designed to evaluate slowing of GA lesion growth in both patients who are at risk for faster progression and in the overall patient population.”

Source: [Annexon Biosciences ARCHER enrollment press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-completes-enrollment-archer-phase-2-trial)

<a id="topic-3.1.2.6.1-4"></a>

##### Regulatory acceptance of GA expansion measured by FAF

> “After extensive discussions, the FDA agreed that an acceptable clinical endpoint for GA could be the rate or extent of anatomic progression of GA in treatment and placebo groups.”
> “Fundus autofluorescence (FAF) imaging is the standard metric used by the FDA for assessing GA expansion.”
> “However, the relationship between function and altered autofluorescence at the GA border is still not clear.”

Source: [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/)

<a id="topic-3.1.2.6.1-5"></a>

##### Sponsor view after the readout: FAF measures the retinal pigment epithelium

> “Lesion growth is measured by fundus autofluorescence (FAF). FAF measures retinal pigment epithelial (RPE) cells under photoreceptors, not photoreceptor cells themselves or their function.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “FAF measures RPE loss/lesion growth, but not photoreceptor or synapse loss and correlates poorly w/ visual function”
> “PRIMARY BIOMARKER ENDPOINT”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.6.1-6"></a>

##### Prespecified visual function endpoints

> “The study included multiple pre-specified visual function measures to assess the effects of vonaprument on vision: change from baseline in BCVA; change from baseline in low-luminance best corrected visual acuity; and change in baseline from low-luminance visual acuity deficit, or LLVD.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

> “PRESPECIFIED SECONDARY FUNCTIONAL ENDPOINTS”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.6.1-7"></a>

##### Best corrected visual acuity: ETDRS letter score

> “BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.6.1-8"></a>

##### BCVA loss of 15 or more letters: definition and rationale

> “Number of Events With Confirmed ≥ 15-Letter Loss BCVA Decline”
> “≥15-letter loss observed for 2 consecutive visits”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

> “In this study, loss was defined as loss of 15 BCVA letters or more on two consecutive visits, or a loss at the end of the 12-month treatment period.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “BCVA ≥15-letter loss universally deemed clinically meaningful”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.6.1-9"></a>

##### Low-luminance visual acuity and low-luminance deficit

> “Low-luminance visual acuity: LLVA is BCVA assessed in low light conditions.”
> “Low-luminance visual deficit: LLVD is the difference between BCVA and LLVA.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “LL-VD will be derived by subtracting LL-BCVA from BCVA.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Participants enrolled

> “ARCHER is a randomized, multi-center, double-masked, placebo-controlled Phase 2 clinical trial that enrolled a total of 270 patients with GA.”

Source: [Annexon Biosciences ARCHER enrollment press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-completes-enrollment-archer-phase-2-trial)

| Enrollment type | Participants |
| --- | --- |
| Actual | “270” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.7.1-2"></a>

##### Participants analyzed by population and arm

| Population | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Baseline (ITT) | “89” | “92” | “89” |
| Primary endpoint (non-subfoveal at baseline) | “38” | “43” | “45” |
| LLVA and LLVD ≥15-letter loss events | “79” | “85” | “79” |
| Safety | “89” | “92” | “89” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

| Population | ANX007 pooled |
| --- | --- |
| Primary endpoint (non-subfoveal at baseline) | “81” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.7.1-3"></a>

##### Optical coherence tomography subpopulation

> “ARCHER study Heidelberg Spectralis OCT population with baseline OCT data (n = 193)”

Source: [Jaffe et al. (2024a)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-V1-Jaffe-FINAL-15Jul24.pdf)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Intent-to-treat and safety populations

> “Intent-to-Treat (ITT) population included all randomized participants.”
> “Safety population included all randomized participants who received at least one dose of study drug.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.7.2-2"></a>

##### Primary endpoint analysis population: non-subfoveal participants

> “Non-subfoveal participants at baseline from the ITT population (all randomized participants).”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.7.2-3"></a>

##### Low-luminance event analyses: participants with a postbaseline measurement

> “Participants with at least 1 postbaseline LLVA measurement in the ITT population (all randomized participants).”
> “Participants with at least 1 postbaseline LLVD measurement in the ITT population (all randomized participants).”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.7.2-4"></a>

##### Primary endpoint model: linear mixed effect model

> “A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups.”
> “The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality.”
> “The GA lesion area was analyzed as reported (that is, not transformed).”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.7.2-5"></a>

##### Visual acuity analyses: chi-square test and MMRM in the ITT population

> “Nominal p-value from a Chi-square test in ITT population”
> “Mean, standard error (SE), and p-value based on MMRM adjusting for baseline lesion location, lesion focality, baseline GA lesion, and the baseline GA lesion by visit interaction.”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.7.2-6"></a>

##### Optical coherence tomography analysis population

> “Heidelberg Spectralis OCT population with baseline OCT data, excludes patients with >98% atrophy at baseline”

Source: [Jaffe et al. (2024a)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-V1-Jaffe-FINAL-15Jul24.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Registry participant flow through the overall study

| Milestone or reason | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Started | “89” | “92” | “89” |
| Received at least 1 dose of study drug | “89” | “92” | “89” |
| Completed | “73” | “77” | “76” |
| Not completed | “16” | “15” | “13” |
| Adverse event | “4” | “7” | “3” |
| Death | “0” | “0” | “1” |
| Lost to follow-up | “2” | “2” | “1” |
| Other than specified | “1” | “0” | “1” |
| Physician decision | “1” | “0” | “1” |
| Protocol violation | “1” | “1” | “0” |
| Withdrawal by subject | “7” | “5” | “6” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.1-2"></a>

##### Counts reported per participant

> “number of participants regardless of which eye was evaluated”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.1-3"></a>

##### Treatment discontinuation by arm

| Measure | Sham pooled | ANX007 EM | ANX007 EOM |
| --- | --- | --- | --- |
| Discontinued treatment | “10 (11.2%)” | “13 (14.6%)” | “11 (12.0%)” |

Source: [EURETINA Congress (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-symposium.pdf)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Registry baseline characteristics, ITT population

| Characteristic | ANX007 EM | ANX007 EOM | Sham | Total |
| --- | --- | --- | --- | --- |
| Participants | “89” | “92” | “89” | “270” |
| Age, years, mean (SD) | “79.7(8.64)” | “80.5(8.53)” | “79.8(7.49)” | “80.0(8.22)” |
| Female, participants | “47” | “60” | “59” | “166” |
| Male, participants | “42” | “32” | “30” | “104” |
| Hispanic or Latino, participants | “1” | “2” | “3” | “6” |
| White, participants | “87” | “89” | “87” | “263” |
| Asian, participants | “1” | “2” | “2” | “5” |
| Study eye GA lesion size, mm², mean (SD) | “7.2789(3.96342)” | “7.5284(4.09946)” | “7.2802(3.98783)” | “7.3643(4.00505)” |
| BCVA, ETDRS letters, mean (SD) | “58.8(17.19)” | “57.9(15.30)” | “58.5(16.23)” | “58.4(16.19)” |
| LLVA, ETDRS letters, mean (SD) | “35.3(16.41)” | “29.6(15.72)” | “34.2(18.05)” | “33.0(16.86)” |
| LLVA and LLVD, participants analyzed | “87 participants” | “91 participants” | “85 participants” | “263 participants” |
| LLVD, ETDRS letters, mean (SD) | “23.5(16.08)” | “28.3(18.39)” | “25.0(15.70)” | “25.7(16.86)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.2-2"></a>

##### Lesion location, lesion size category, fellow-eye CNV, and multifocality

| Characteristic | Sham pooled (N=89) | Vonaprument EM (N=89) | Vonaprument EOM (N=92) |
| --- | --- | --- | --- |
| Foveal lesion | “49.4%” | “57.3%” | “53.3%” |
| GA lesion < 7.5 mm² | “61.8%” | “58.4%” | “57.6%” |
| Fellow eye CNV | “22.5%” | “24.7%” | “17.4%” |
| Multifocality, n (%) | “65 (73.0%)” | “61 (68.5%)” | “67 (72.8%)” |

Source: [Lally (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Lally-Retina-Society-2025-Final.pdf)

<a id="topic-3.1.2.8.2-3"></a>

##### Company summary of baseline characteristics

> “Patients were nearly equally split between foveal (49.4% to 57.3%) and non-foveal groups, had an average age of 80 years and were balanced between female and male.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Patients had an average age of 80 years and, importantly, were well balanced for baseline visual acuity (BCVA between 58.3 and 58.5).”

Source: [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary endpoint: rate of change in geographic atrophy lesion area through month 12, registry results

| Measure | ANX007 EM | ANX007 EOM | ANX007 Pooled | Sham |
| --- | --- | --- | --- | --- |
| Participants analyzed | “38” | “43” | “81” | “45” |
| Rate of change (slope), mean (SE), mm²/year | “1.9902(0.36343)” | “2.1575(0.34824)” | “2.0837(0.30177)” | “1.9019(0.34239)” |
| Change from baseline to month 12, least squares mean (SE), mm² | “2.3547(0.26452)” | “2.5782(0.24317)” | “2.4835(0.18003)” | “2.3170(0.23142)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

> “Non-subfoveal participants at baseline from the ITT population (all randomized participants).”
> “A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.3-2"></a>

##### Primary endpoint: company-reported reduction in lesion growth

> “The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance. A 6.2% reduction in lesion growth was observed in monthly treatment group (p=0.526), a 1.3% reduction was observed in the every-other-month treatment group (p-value=0.896) and a 3.7% reduction was observed in the pooled patient population (p-value=0.673).”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.3-3"></a>

##### Lesion growth by study period: additional analysis

> “While the primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance in the ARCHER trial, additional analyses showed that ANX007’s effect on lesion size showed a trend toward greater effect in the second six months of study for both treatment groups, suggesting that ANX007’s impact on lesion growth may increase with time.”

Source: [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)

> “No significant reduction at month 12, but effects increased over 2nd half of study”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-4"></a>

##### Confirmed BCVA ≥15-letter loss: registry event counts, secondary outcome

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Participants analyzed | “89” | “92” | “89” |
| Number of events with confirmed ≥15-letter loss | “4” | “8” | “15” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

> “Confirmed ETDRS BCVA ≥15-letter loss was deﬁned as ≥15-letter loss observed for 2 consecutive visits.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.3-5"></a>

##### Confirmed BCVA ≥15-letter loss: topline company counts and event definition

> “In this study, loss was defined as loss of 15 BCVA letters or more on two consecutive visits, or a loss at the end of the 12-month treatment period.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Measure | Sham (n=89) | EM (n=89) | EOM (n=92) | ANX007 pooled (n=181) |
| --- | --- | --- | --- | --- |
| Participants with ≥15-letter loss through month 12 | “21.3% (19/89)” | “5.6% (5/89)” | “10.9% (10/92)” | “8.3% (15/181)” |
| p-value vs sham | “--” | “0.0021” | “0.055” | “0.0024” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Over the 12-month treatment period, patients in the ANX007 monthly treatment group showed a 72% reduction in risk of >15-letter vision loss (n=89, p=0.006) and patients in the ANX007 every-other-month treatment group showed a 48% reduction in risk of >15-letter vision loss (n=92, p=0.064). Patients in the pooled treatment group showed a 59% reduction in risk of >15-letter loss (n=181, p=0.008).”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.3-6"></a>

##### Confirmed BCVA ≥15-letter loss: final data under two event definitions

| Event definition and measure | Sham | Vonaprument EM | Vonaprument EOM |
| --- | --- | --- | --- |
| Through month 12 or last visit: participants with loss | “19/89” | “5/89” | “9/92” |
| Through month 12 or last visit: percentage | “21.3%” | “5.6%” | “9.8%” |
| Through month 12 or last visit: nominal p-value vs pooled sham | “---” | “0.0021” | “0.032” |
| Month 12 event confirmed at month 15: participants with loss | “15/89” | “4/89” | “8/92” |
| Month 12 event confirmed at month 15: percentage | “16.9%” | “4.5%” | “8.7%” |
| Month 12 event confirmed at month 15: nominal p-value vs pooled sham | “---” | “0.0076” | “0.0994” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Confirmed for two consecutive visits through month 12 or at last study visit”
> “Confirmed at two consecutive visits through month 12; month 12 event confirmed at month 15”
> “Nominal p-value from a Chi-square test in ITT population”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-7"></a>

##### Confirmed BCVA ≥15-letter loss: analysis type and nominal significance

> “Monthly treatment with vonaprument demonstrated nominally statistically significant reduction in BCVA ≥15-letter loss (p=0.0021) compared to sham. The persistent ≥15-letter BCVA loss through month 12 hazard was reduced 72% in the monthly arm (p=0.006) and 48% in the every other month arm (p=0.064).”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

> “Results: Fewer Patients Treated with ANX007 Had Confirmed BCVA ≥15-Letter Loss Through Month 12”
> “A Prespecified Secondary Analysis”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

> “Confirmed loss of 15 or more ETDRS letters as measured by BCVA”
> “was a prespecified analysis in ARCHER (loss events defined as occurring at two consecutive study visits, including month 12)”

Source: [Epshtein (2026)](https://annexonbio.com/wp-content/uploads/2026/09/Epshtein-AAOptom-Poster-.pdf)

<a id="topic-3.1.2.8.3-8"></a>

##### Time to confirmed BCVA ≥15-letter loss: Kaplan-Meier hazard ratios

> “73% Risk Reduction Vonaprument EM”
> “HR (CI) = 0.272 (0.090 to 0.819); Nominal p = 0.0119”
> “50% Risk Reduction Vonaprument EOM”
> “HR (CI) = 0.504 (0.214 to 1.189); Nominal p = 0.1098”
> “HR, hazard ratio; Nominal log-rank test (versus sham) p-values are presented”
> “Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-9"></a>

##### Time to confirmed BCVA ≥15-letter loss: hazard ratios as presented in 2024

> “53% Risk Reduction ANX007 EOM”
> “HR (CI) = 0.504 (0.214 to 1.190); p = 0.0788”
> “73% Risk Reduction ANX007 EM”
> “HR (CI) = 0.272 (0.090 to 0.819); p = 0.0098”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.8.3-10"></a>

##### Confirmed BCVA ≥10-letter and ≥20-letter loss: sensitivity analysis

| Threshold and measure | Sham | EM | EOM |
| --- | --- | --- | --- |
| ≥10-letter loss: participants with loss | “23/89” | “14/89” | “19/92” |
| ≥10-letter loss: percentage | “25.8%” | “15.7%” | “20.7%” |
| ≥10-letter loss: nominal p-value vs sham | “---” | “0.096” | “0.408” |
| ≥20-letter loss: participants with loss | “15/89” | “4/89” | “6/92” |
| ≥20-letter loss: percentage | “16.9%” | “4.5%” | “6.5%” |
| ≥20-letter loss: nominal p-value vs sham | “---” | “0.008” | “0.030” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Confirmed for two consecutive visits through month 12 or at last visit”
> “Nominal p-value from a Chi-square test in ITT population”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-11"></a>

##### Additional analyses of BCVA loss presented in 2023

> “Annexon conducted additional analyses to further evaluate the effect of ANX007 treatment on BCVA and GA lesion area.”
> “Risk reduction for BCVA ≥15 letter loss was maintained in a more conservative analysis, in which events occurring at the last single-point visit were excluded.”
> “ANX007’s impact on BCVA ≥15 letter loss was consistent across patients’ baseline characteristics, including lesion size, lesion location, multifocality and others, and was not driven by any one patient subgroup.”
> “In a fellow-eye analysis, comparison of sham, monthly (EM) and every-other-month (EOM) treatment groups in the subset of patients with bilateral GA, a consistent dose-dependent trend for protection against ≥15 BCVA letter loss at the 12-month time point was shown. No protection was demonstrated in sham whereas a 74% reduction for EM and 47% reduction for EOM was demonstrated against the corresponding fellow eye groups.”

Source: [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)

<a id="topic-3.1.2.8.3-12"></a>

##### BCVA ≥15-letter loss after treatment ended: off-treatment period

> “In a preliminary 6-month off-treatment analysis assessing vision loss after ANX007 treatment was discontinued, the rate of decline in patients with BCVA ≥15 letter loss in the treated groups accelerated to parallel the decline in the sham group.”

Source: [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)

> “Low frequency (<0.6% per month) of single BCVA ≥15-letter losses in EM- and EOM-treated groups during 12-month treatment period”
> “While benefit was maintained after treatment cessation the rate of BCVA≥15 LL increased to parallel that of sham (>1.6% per month)”

Source: [Khurana (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Khurana-MacSoc-2025-Central-Subdomains-.pdf)

<a id="topic-3.1.2.8.3-13"></a>

##### Mean change in BCVA from baseline to month 12

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Participants analyzed | “89” | “92” | “89” |
| Mean (SE) change, letters | “-1.7(1.33)” | “-2.6(1.29)” | “-4.1(1.31)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

| Measure | Sham | EM | EOM |
| --- | --- | --- | --- |
| Nominal p-value vs sham, mean change in BCVA at month 12 | “---” | “0.1904” | “0.3977” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Nominal p-value from MMRM adjusting for baseline lesion location, lesion focality, baseline GA lesion, and the baseline GA lesion by visit interaction in ITT population”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-14"></a>

##### Low-luminance visual acuity: registry results

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Change from baseline to month 12, least squares mean (SE), letters | “-1.4(1.29)” | “-2.8(1.25)” | “-4.8(1.31)” |
| Participants analyzed for ≥15-letter loss | “79” | “85” | “79” |
| Number of events with ≥15-letter LLVA loss | “6” | “8” | “16” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

> “LLVA ≥15-letter loss worsening from Baseline during the 12-month Treatment.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.3-15"></a>

##### Low-luminance visual acuity ≥15-letter loss: topline company counts

> “Low-luminance visual acuity: LLVA is BCVA assessed in low light conditions. ANX007 demonstrated a non-significant trend in slowing the progression of LLVA loss in the monthly, every-other-month and pooled treatment groups, which Annexon believes supports the ANX007 mechanism of action”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Measure | Sham (n=79) | EM (n=79) | EOM (n=85) | ANX007 pooled (n=164) |
| --- | --- | --- | --- | --- |
| Participants with ≥15-letter LLVA loss through month 12 | “20.3% (16/79)” | “10.1% (8/79)” | “11.8% (10/85)” | “11.0% (18/164)” |
| p-value vs sham | “--” | “0.076” | “0.14” | “0.051” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.3-16"></a>

##### Low-luminance visual acuity and deficit: final data

| Measure | Sham | EM | EOM |
| --- | --- | --- | --- |
| LLVA ≥15-letter loss: participants with loss | “16/79” | “6/79” | “8/85” |
| LLVA ≥15-letter loss: percentage | “20.3%” | “7.6%” | “9.4%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “--” | “0.0216” | “0.0497” |
| LLVD ≥15-letter worsening: participants with worsening | “13/79” | “4/79” | “8/85” |
| LLVD ≥15-letter worsening: percentage | “16.5%” | “5.1%” | “9.4%” |
| LLVD ≥15-letter worsening: nominal p-value vs sham | “--” | “0.0209” | “0.1774” |
| Mean change in LLVA at month 12 | “-4.8” | “-1.4” | “-2.8” |
| Mean change in LLVA at month 12: nominal p-value vs sham | “---” | “0.0592” | “0.2664” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Patients with at least one post-baseline LLVA measurement and two consecutive or last visit 15-letter loss events”
> “≥15-letter worsening in LLVD was defined as a change from Baseline of ≥15-letters across 2 consecutive visits, or at the last visit, through month 12”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-17"></a>

##### Low-luminance visual acuity ≥15-letter loss: event definition as presented in 2024

| Measure | Sham | EM | EOM |
| --- | --- | --- | --- |
| LLVA ≥15-letter loss: participants with loss | “16/79” | “6/79” | “8/85” |
| LLVA ≥15-letter loss: percentage | “20.3%” | “7.6%” | “9.4%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “--” | “0.022” | “0.050” |

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

> “Patients with single LLVA ≥15-letter loss event and at least one post-baseline LLVA measurement”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

> “Statistically significant protection of vision in low light conditions, low luminance visual acuity (LLVA) at month 12, which is an important assessment of visual performance for everyday activity (LLVA ≥15-letter loss at month 12: 20.3% (sham) vs. 7.6% (ANX007 monthly); p = 0.022)”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.2.8.3-18"></a>

##### Low-luminance visual deficit: registry results

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Change from baseline to month 12, least squares mean (SE), letters | “-0.4(1.55)” | “1.3(1.50)” | “0.6(1.57)” |
| Participants analyzed for ≥15-letter worsening | “79” | “85” | “79” |
| Number of events with ≥15-letter LLVD worsening | “4” | “8” | “13” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.3-19"></a>

##### Ellipsoid zone loss: photoreceptor preservation across the macula and in central subdomains

| Region | Sham participants | Vonaprument pooled participants | Reduction vs sham | Nominal p-value |
| --- | --- | --- | --- | --- |
| Pan-macula, total EZ loss | “Sham (n = 67)” | “Vonaprument pooled (n = 107)” | “27% decrease” | “0.0457” |
| Central 2.0 mm, total EZ loss | “Sham (n = 25)” | “Vonaprument pooled (n = 36)” | “48% decrease” | “0.0218” |
| Central 1.5 mm, total EZ loss | “Sham (n = 22)” | “Vonaprument pooled (n = 24)” | “59% decrease” | “0.0319” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Nominal p-values from a linear mixed model for repeated measures model (slope) analysis”
> “Heidelberg Spectralis OCT population with baseline OCT data, excludes patients with >98% atrophy/attenuation at baseline”
> “Vonaprument treatment arms were not statistically different”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Prespecified analyses included best-corrected visual acuity (BCVA) ≥15-letter loss at 2 consecutive visits and changes from baseline in EZ and RPE structure.”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

<a id="topic-3.1.2.8.3-20"></a>

##### Ellipsoid zone and central retinal pigment epithelium loss: results as reported in 2024

> “ANX007 provided up to 60% protection of photoreceptors compared to sham within the central 1.5 mm of the fovea, as measured by ellipsoid zone (EZ) through 12 months (p = 0.0319*)”
> “ANX007 provided 29% protection of photoreceptors across the full retinal field as measured by EZ through 12 months (p = 0.017*)”
> “ANX007 demonstrated a trend of protection against RPE loss in the central foveal subfield, the region where RPE loss best correlates with vision loss (18% protection of RPE loss, p = 0.40*). RPE loss is a measure that lags behind photoreceptor loss.”
> “*nominal p-value”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.2.8.3-21"></a>

##### Subgroup analysis: BCVA ≥15-letter loss by lesion location

> “When assessing the BCVA treatment effect by lesion location, the combined analysis, stratified by foveal and non-foveal patients, demonstrated an overall statistically significant difference between ANX007 and sham”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Lesion location | Sham | EM | EOM | ANX007 pooled |
| --- | --- | --- | --- | --- |
| Foveal | “25.0% (11/44)” | “5.9% (3/51)” | “18.4% (9/49)” | “12.0% (12/100)” |
| Non-foveal | “17.8% (8/45)” | “5.3% (2/38)” | “2.3% (1/43)” | “3.7% (3/81)” |
| p-value vs sham | “--” | “0.0019” | “0.0439” | “0.0015” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Nominal p-value from a Cochran Mantel-Haenszel test (General Association) in ITT population”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-22"></a>

##### Subgroup analysis: BCVA ≥15-letter loss by baseline low-luminance visual deficit

> “When assessing the BCVA treatment effect by retinal health, the combined analysis, stratified by healthier and less healthy retina, demonstrated an overall statistically significant difference between ANX007 and sham. This effect supports the potential use as an early treatment for GA”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Baseline LLVD | Sham | EM | EOM | ANX007 pooled |
| --- | --- | --- | --- | --- |
| LLVD <30 (healthier) | “16.9% (10/59)” | “0.0% (0/56)” | “6.3% (3/48)” | “2.9% (3/104)” |
| LLVD ≥30 (less healthy) | “30.8% (8/26)” | “16.1% (5/31)” | “16.3% (7/43)” | “16.2% (12/74)” |
| p-value vs sham | “--” | “0.0016” | “0.029” | “0.0009” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Additional analyses were conducted to evaluate the effect of ANX007 on these measures in participants with relatively less advanced disease at baseline (less EZ loss and lower low luminance visual deficit [LLVD]).”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

<a id="topic-3.1.2.8.3-23"></a>

##### Subgroup analysis: low-luminance visual deficit worsening by baseline BCVA

| Baseline BCVA score | Sham | EM | EOM | ANX007 pooled |
| --- | --- | --- | --- | --- |
| ≥55 (better vision) | “25.5% (13/51)” | “9.4% (5/53)” | “16.4% (9/55)” | “13.0% (14/108)” |
| <55 (impaired vision) | “17.9% (5/28)” | “7.7% (2/26)” | “3.3% (1/30)” | “5.4% (3/56)” |
| p-value vs sham | “--” | “0.0161” | “0.0597” | “0.0091” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.3-24"></a>

##### Post hoc analysis: participants with subfoveal lesions at baseline

| Measure, subfoveal population | Sham | Vonaprument EM | Vonaprument EOM |
| --- | --- | --- | --- |
| Confirmed BCVA ≥15-letter loss: participants with loss | “10/44” | “3/51” | “7/49” |
| Confirmed BCVA ≥15-letter loss: percentage | “22.7%” | “5.9%” | “14.3%” |
| Confirmed BCVA ≥15-letter loss: nominal p-value vs sham | “---” | “.0172” | “.2930” |
| LLVA ≥15-letter loss: participants with loss | “7/41” | “2/50” | “1/48” |
| LLVA ≥15-letter loss: percentage | “17.1%” | “4.0%” | “2.1%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “---” | “.0137” | “.0377” |

Source: [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf)

> “76% Risk Reduction Vonaprument EM”
> “HR (CI) = 0.242 (0.067 to 0.881); Nominal p = .0204”
> “41% Risk Reduction Vonaprument EOM”
> “HR (CI) = 0.504 (0.225 to 1.555); Nominal p = .2784”
> “Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit; visits were monthly through Month 12 and then at Months 15 and 18”
> “Historically, GA with subfoveal involved lesions was considered too advanced to show a meaningful treatment benefit”

Source: [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf)

<a id="topic-3.1.2.8.3-25"></a>

##### Baseline characteristics associated with BCVA ≥15-letter loss

> “BCVA ≥15-letter loss did not occur in participants with baseline BCVA <44 letters”
> “BCVA ≥15-letter loss less frequent in participants with baseline BCVA >69 letters”
> “Confirmed loss of 15 or more BCVA letters was associated with:”
> “Baseline visual acuity (BCVA) above 45 letters (20/100)”
> “All lesion types – more strongly associated in those with subfoveal lesions”

Source: [Chang (2026)](https://annexonbio.com/wp-content/uploads/2026/07/MChang-ASRS-Presentation-FINAL-18Jul26.pptx.pdf)

<a id="topic-3.1.2.8.3-26"></a>

##### Number needed to treat

> “Number Needed to Treat = 1 / (21.3 – 5.6) * 100= 6.4”
> “For every 7 patients treated with ANX007 monthly, 1 additional patient would be spared clinically significant vision loss”
> “Number Needed to Treat EM To Avoid ≥10 LL = 10”
> “Number Needed to Treat EM To Avoid ≥15 LL = 7”
> “Number Needed to Treat EM To Avoid ≥20 LL = 8”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

Additional sources: [Jaffe et al. (2024a)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-V1-Jaffe-FINAL-15Jul24.pdf); [Jaffe et al. (2024b)](https://annexonbio.com/wp-content/uploads/2024/09/Retina-2024-FINAL-9Sept24.pdf); [Chakravarthy et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-Chakravarthy-FINAL.pdf); [Khurana et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/10/AAO-2024-poster-final.pdf); [Heier et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Heier-FloRetina-Final-Dec-2024.pdf); [Stanga et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Stanga-FloRetina-Final-Dec24.pdf); [Kuriyan et al. (2025)](https://annexonbio.com/wp-content/uploads/2025/05/04_11_2025_ARVO_-Kuriyan_FINAL.pdf); [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf); [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf); [Sharma (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Sharma-Euretina.pdf); [Williams et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Williams-AAO-Vision-Loss-in-Eyes-with-Subfoveal-RPE-Lesions-in-GA-Post-Hoc-Analysis-of-the-ARCHER-Trial.pdf)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Treatment-emergent adverse events through month 12, registry results

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Participants analyzed | “89” | “92” | “89” |
| Participants with TEAEs | “65” | “68” | “68” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

> “Safety population included all randomized participants who received at least one dose of study drug.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-2"></a>

##### Deaths, serious adverse events, and other adverse events, registry results

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| All-cause mortality | “2/89 (2.25%)” | “3/92 (3.26%)” | “2/89 (2.25%)” |
| Participants with serious adverse events | “21/89 (23.60%)” | “16/92 (17.39%)” | “16/89 (17.98%)” |
| Participants with other (non-serious) adverse events | “21/89 (23.60%)” | “20/92 (21.74%)” | “23/89 (25.84%)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-3"></a>

##### Ocular serious adverse events, registry results

| Serious adverse event | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Endophthalmitis | “1/89 (1.12%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Retinal artery occlusion | “0/89 (0.00%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Neovascular age-related macular degeneration | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Dry age-related macular degeneration | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Iritis | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Vitritis | “0/89 (0.00%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Vitreous floaters | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Visual acuity reduced | “0/89 (0.00%)” | “0/92 (0.00%)” | “1/89 (1.12%)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-4"></a>

##### Non-ocular serious adverse events in two or more participants in any group, registry results

| Serious adverse event | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Atrial fibrillation | “2/89 (2.25%)” | “4/92 (4.35%)” | “0/89 (0.00%)” |
| Acute myocardial infarction | “2/89 (2.25%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Angina pectoris | “0/89 (0.00%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Pneumonia | “3/89 (3.37%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Urinary tract infection | “1/89 (1.12%)” | “1/92 (1.09%)” | “2/89 (2.25%)” |
| Cerebrovascular accident | “2/89 (2.25%)” | “0/92 (0.00%)” | “2/89 (2.25%)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-5"></a>

##### Non-serious adverse events at a frequency of 5% or more, registry results

| Adverse event | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| COVID-19 | “12/89 (13.48%)” | “10/92 (10.87%)” | “10/89 (11.24%)” |
| Urinary tract infection | “6/89 (6.74%)” | “7/92 (7.61%)” | “12/89 (13.48%)” |
| Conjunctival haemorrhage | “7/89 (7.87%)” | “6/92 (6.52%)” | “3/89 (3.37%)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-6"></a>

##### Adverse events of special interest: choroidal neovascularization, endophthalmitis, vascular occlusion, vasculitis, intraocular inflammation, and ischemic optic neuropathy

| Adverse event, n (%) | Sham (N=89) | Vonaprument EM (N=89) | Vonaprument EOM (N=92) |
| --- | --- | --- | --- |
| Choroidal neovascularization | “3 (3.4%)” | “4 (4.5%)” | “4 (4.3%)” |
| Endophthalmitis | “0” | “1 (1.1%)” | “2 (2.2%)” |
| Retinal vascular occlusion | “0” | “0” | “1^ (1.1%)” |
| Retinal vasculitis | “0” | “0” | “0” |
| Intraocular inflammation | “0” | “2 (2.2%)” | “1 (1.1%)” |
| Ischemic optic neuropathy | “0” | “0” | “0” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Iritis – 1”
> “Resolved with topical steroids in 2 days”
> “Vitritis – 1”
> “Resolved with topical steroids in 9 days”
> “Vitreous Debris – 1”
> “KP on endothelium, prior treatment with topical steroids”
> “Isolated cilioretinal artery occlusion; no vasculitis confirmed by DSMC and reading center”
> “Not AESI, included because of current interest”
> “CNV rate generally similar across sham and treatment arms”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.5-7"></a>

##### Endophthalmitis, intraocular inflammation, and retinal artery occlusion: topline description

> “Among the patients treated with ANX007, three serious adverse events (SAEs) of endophthalmitis were observed, which were determined to be related to intravitreal injection procedure and not related to treatment. There were three SAEs of intraocular inflammation, suspected of being treatment-related, which were not associated with retinal vasculitis. One SAE of retinal artery occlusion was reported, suspected of being treatment-related, which was also not associated with retinal vasculitis.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.5-8"></a>

##### Choroidal neovascularization and retinal vasculitis

> “There was a limited incidence of choroidal neovascularization (CNV) conversion across all three groups, with 3.4% in the sham group vs. 4.5% and 4.3% in the ANX007 monthly and every-other-month groups, respectively.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Vonaprument treatment was generally well-tolerated, with no increase in CNV rates between the treated and sham arms and no events of retinal vasculitis reported.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: missed primary endpoint, reliance on secondary and post hoc analyses, and unpublished results

- Primary endpoint: ARCHER did not meet its primary endpoint, the rate of change (slope) in geographic atrophy lesion area by fundus autofluorescence from baseline to month 12. In the registry analysis, which included non-subfoveal participants only, the slope was 2.0837 mm²/year in 81 participants receiving pooled vonaprument and 1.9019 mm²/year in 45 participants receiving sham. Annexon reported reductions in lesion growth of 6.2% with monthly dosing (p=0.526), 1.3% with every-other-month dosing (p=0.896), and 3.7% for the pooled groups (p=0.673).
- Efficacy claims rest on secondary, exploratory, and post hoc analyses: BCVA ≥15-letter loss is a secondary outcome on the registry record and is labeled “A Prespecified Secondary Analysis” in a 2025 presentation. The Form 10-K describes the monthly-arm result as “nominally statistically significant”, and the company presentations of 2024 to 2026 label their p-values as nominal. The analyses of eyes with subfoveal lesions are labeled post hoc, and the company describes the analyses of less advanced disease, BCVA ≥10-letter and ≥20-letter loss, fellow eyes, and the off-treatment period as additional or sensitivity analyses. Mean change in BCVA at month 12 was -1.7 letters with monthly dosing, -2.6 with every-other-month dosing, and -4.1 with sham, with nominal p-values of 0.1904 and 0.3977.
- Discrepant event counts: the registry reports 4, 8, and 15 events of confirmed BCVA ≥15-letter loss (monthly, every other month, sham), defined as loss at 2 consecutive visits. The topline release reported 5 of 89 (5.6%), 10 of 92 (10.9%), and 19 of 89 (21.3%) participants, counting loss on two consecutive visits or a loss at the end of the 12-month treatment period. The 2026 presentation reports 5 of 89, 9 of 92, and 19 of 89 under “two consecutive visits through month 12 or at last study visit” (nominal p=0.0021 and 0.032), and 4 of 89, 8 of 92, and 15 of 89 when the month 12 event is confirmed at month 15 (nominal p=0.0076 and 0.0994). Under the definition that reproduces the registry counts, the every-other-month result is not nominally significant.
- Changing analyses between presentations: the topline release reported LLVA ≥15-letter loss in 8 of 79 participants (10.1%) with monthly dosing and 16 of 79 (20.3%) with sham (p=0.076), described as a “non-significant trend”. Later presentations report 6 of 79 (7.6%) with p=0.022 or 0.0216; the 2024 presentation attributes these counts to a “single LLVA ≥15-letter loss event”, and the 2026 presentation attributes the same counts to “two consecutive or last visit 15-letter loss events”. The nominal p-value for the monthly hazard ratio of 0.272 is 0.0098 in the 2024 presentation and 0.0119 in the 2026 presentation, and for the every-other-month hazard ratio of 0.504 it is 0.0788 and 0.1098. The ellipsoid zone result across the full retinal field was 29% (p=0.017) in the 2024 release and a 27% decrease (p=0.0457) in 107 vonaprument and 67 sham participants in the 2026 presentation; the central 1.5 mm and 2.0 mm subdomain analyses include 46 and 61 participants.
- No peer-reviewed publication: no journal article reporting ARCHER results was identified. The registry record states a restrictive agreement under which investigator-initiated publications wait until all protocol-defined results are published in a manuscript. The available results come from the registry, press releases, the Form 10-K, investor presentations, and congress presentations that state Annexon sponsorship, with authors who are employees and equity owners of Annexon Biosciences.
- Applicability: the treatment period was 12 months, followed by 6 months off treatment, during which the rate of BCVA ≥15-letter loss in the treated groups increased to parallel sham. Ninety-six percent of participants were enrolled in the United States. ARCHER II did not enroll individuals with baseline BCVA <45 letters, because ARCHER showed a very low incidence of BCVA 15-letter loss in that group, so the phase 3 population differs from the phase 2 population. The phase 3 trial tests monthly dosing only.

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results); [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic); [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting); [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program); [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c); [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf); [Khurana (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Khurana-MacSoc-2025-Central-Subdomains-.pdf); [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf); [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf); [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf); [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf)

<a id="topic-3.1.2.9-2"></a>

#### Primary endpoint not met

> “Reduction in rate of geographic atrophy lesion growth did not reach statistical significance”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “While the primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance, greater impact on retinal pigment epithelium loss was observed in the second six months of treatment versus the first.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-3.1.2.9-3"></a>

#### Restrictive publication agreement on the registry record

> “Written approval from the Sponsor is required before disclosing any information relative to this clinical study, and no publications initiated by Investigators may be published until all protocol-defined results are published in a manuscript.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.9-4"></a>

#### Post hoc analyses with nominal p-values

> “Post-hoc analysis; all p-values are nominal”

Source: [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf)

<a id="topic-3.1.2.9-5"></a>

#### Sponsor employment and sponsorship of congress presentations

> “SB, LT, RD, XT, WLC: Employment with and equity ownership in Annexon Biosciences, Inc.”
> “These studies sponsored by Annexon Biosciences (Brisbane, California, USA)”

Source: [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf)

> “Vladislav Volman, Scott Borland, Lori Taylor, Kimberly Reed, W. Lloyd Clark, Margot Goodkin, Erik Pulkstenis, Jamie Dananberg, Ted Yednock, Alessia Tassoni: Owners and Employees of Annexon Biosciences”

Source: [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf)

<a id="topic-3.1.2.9-6"></a>

#### Phase 3 population restricted after the phase 2 results

> “Individuals with baseline BCVA <45 letters not enrolled in ARCHER II due to very low incidence of BCVA 15-letter loss in ARCHER”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.9-7"></a>

#### Enrollment concentrated in the United States

> “Ninety-six percent of patients enrolled were from the United States.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
